Journal of Rheumatic Diseases

Table. 1.

Baseline characteristics of patients

Characteristic Patients (n=91)
Age (yr) 55.7±13.3
Age group
18∼34 yr 7 (7.7)
35∼44 yr 9 (9.9)
45∼54 yr 18 (19.8)
55∼64 yr 34 (37.4)
65∼74 yr 18 (19.8)
≥75 yr 5 (5.5)
Sex, female 64 (70.3)
Disease duration* (yr) 7.67±7.34
Comorbidities 23 (25.3)
Diabetes 9 (9.9)
Chronic pulmonary disease 5 (5.5)
Cerebrovascular disease 4 (4.4)
DAS28 6.1±1.0
DAS28 categorization
Moderate disease activity 6 (6.6)
High disease activity 85 (93.4)
Concomitant disease modifying antirheumatic drug 28 (30.8)
Methotrexate 23 (25.3)
Leflunomide 13 (14.3)
Hydroxychloroquine 11 (12.1)
Sulfasalazine 3 (3.3)
Concomitant oral steroids 23 (25.3)

Values are presented as mean±standard deviation or number (%). *Disease duration=Year of index visit-Year of diagnosis.DAS28-CRP or DAS28-ESR.

J Rheum Dis 2021;28:68~75 https://doi.org/10.4078/jrd.2021.28.2.68
© J Rheum Dis